Subscribe
shutterstock_1654522180_romana_cross
Romana Cross / Shutterstock.com
14 December 2021AmericasMuireann Bolger

3M stumbles in litigation strategy over COVID-19 masks

Multinational 3M has suffered a setback in its litigation campaign against the distributors of N95 masks after a US judge found in favour of arguments made by one of its opponents.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
3M wins injunction against Florida counterfeit mask seller
21 January 2021   3M has secured an injunction against a Florida company it has accused of selling more than 10,000 counterfeit versions of its N95 face masks at the US District Court for the District of Minnesota.
Americas
3M settles mask price-gouging suit
28 October 2020   A Minnesota judge has approved an agreement between 3M and a former Marine, resolving a price-gouging dispute over N95 masks.


Editor's picks

Killing the golden goose of US drug innovation (Part II): Drug pricing myths
Americas
Killing the golden goose of US drug innovation (Part II): Drug pricing myths
12 September 2025

Editor's picks

Americas
Killing the golden goose of US drug innovation (Part II): Drug pricing myths
12 September 2025
Americas
Smart ringleader: Could Ōura’s market dominance be under threat?
5 September 2025
Americas
Why Masimo’s ‘rare’ move pushes Apple case into uncharted territory
3 September 2025
Europe
Sandoz blocked by UK court from seeking Xarelto profits
2 September 2025
Europe
UPC sees rising small molecule litigation with Pfizer in the hot seat
29 August 2025
Europe
Astellas win strengthens blockbuster drug's European position
20 August 2025

More features

How 'Boehringer' sets preliminary relief threshold for generics
The Quintara decision: Defining trade secrets in federal cases
To disclose or not: Pharma patents face new AI reality
Trade secrets go global: How brand owners face a high-stakes battlefront
Killing the golden goose of US drug innovation (Part II): Drug pricing myths
Former pharma GC brings in-house perspective to McGuireWoods
Sandoz eyes US biosimilar launch as Regeneron settles
Killing the golden goose of US drug innovation (Part I): Follow the money